Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 560Carcinoma, Non-Small-Cell Lung 517Prostatic Neoplasms 336Colorectal Neoplasms 273Neoplasms 269Multiple Myeloma 267Leukemia, Myeloid, Acute 225Squamous Cell Carcinoma of Head and Neck 217Lung Neoplasms 211Neoplasm Metastasis 205Carcinoma, Hepatocellular 198Melanoma 175Triple Negative Breast Neoplasms 174Pancreatic Neoplasms 172Recurrence 153Ovarian Neoplasms 152Lymphoma 142Glioblastoma 136Brain Neoplasms 134Sarcoma 131Carcinoma, Renal Cell 129Lymphoma, Large B-Cell, Diffuse 126Leukemia, Lymphocytic, Chronic, B-Cell 126Stomach Neoplasms 125Head and Neck Neoplasms 125Precursor Cell Lymphoblastic Leukemia-Lymphoma 110Rectal Neoplasms 109Myelodysplastic Syndromes 104Uterine Cervical Neoplasms 100Urinary Bladder Neoplasms 100

Interventions

Taxes 1Gemcitabine 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Metastatic Pancreatic Adenocarcinoma × 1 year × Clear all
NCT06576115 2025-11-05

Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer

Barbara Ann Karmanos Cancer Institute

Phase 2 Recruiting
30 enrolled
Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡